Richard Simcock

Richard Simcock

Auto-generated profile, based on publicly available information

Richard Simcock

University Hospitals Sussex NHS Foundation Trust, Brighton, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in The Lancet
Verified
Journal Article
Open access
HEHelena M Earl
Helena M Earl
LHLouise Hiller
Louise Hiller
AVAnne-Laure Vallier
Anne-Laure Vallier
SLShrushma Loi
Shrushma Loi
KMKaren McAdam
Karen McAdam
SYSundus Yahya
Sundus Yahya
Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival. This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly assigned patients with HER2-positive early breast cancer, aged 18 years or older, and with a clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either 6-month or 12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg) or subcutaneously (600 mg), given in combination with chemotherapy (concurrently or sequentially). The primary endpoint was disease-free survival, analysed by intention to treat, with a non-inferiority margin of 3% for 4-year disease-free survival. Safety was analysed in all patients who received trastuzumab. This trial is registered with EudraCT (number 2006-007018-39), ISRCTN (number 52968807), and ClinicalTrials.gov (number NCT00712140). Between Oct 4, 2007, and July 31, 2015, 2045 patients were assigned to 12-month trastuzumab treatment and 2044 to 6-month treatment (one patient was excluded because they were double randomised). Median follow-up was 5·4 years (IQR 3·6-6·7) for both treatment groups, during which a disease-free survival event occurred in 265 (13%) of 2043 patients in the 6-month group and 247 (12%) of 2045 patients in the 12-month group. 4-year disease-free survival was 89·4% (95% CI 87·9-90·7) in the 6-month group and 89·8% (88·3-91·1) in the 12-month group (hazard ratio 1·07 [90% CI 0·93-1·24], non-inferiority p=0·011), showing non-inferiority of the 6-month treatment. 6-month trastuzumab treatment resulted in fewer patients reporting severe adverse events (373 [19%] of 1939 patients vs 459 [24%] of 1894 patients, p=0·0002) or stopping early because of cardiotoxicity (61 [3%] of 1939 patients vs 146 [8%] of 1894 patients, p<0·0001). We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events. These results support consideration of reduced duration trastuzumab for women at similar risk of recurrence as to those included in the trial. UK National Institute for Health Research, Health Technology Assessment Programme.

1 May 2020 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
RSRichard Simcock
Richard Simcock
TTToms Vengaloor Thomas
Toms Vengaloor Thomas
CEChristopher Estes
Christopher Estes
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
MKMatthew S. Katz
Matthew S. Katz
HSHina Saeed
Hina Saeed
As the global COVID-19 pandemic escalates there is a need within radiation oncology to work to support our patients in the best way possible. Measures are required to reduce infection spread between patients and within the workforce. Departments need contingency planning to create capacity and continue essential treatments despite a reduced workforce. The #radonc community held an urgent online journal club on Twitter in March 2020 to discuss these issues and create some consensus on crucial next steps. There were 121 global contributors. This document summarises these discussions around themes of infection prevention, rationalisation of workload and working practice in the presence of infection.

1 September 2020 in Clinical Oncology
Verified
Journal Article
Closed access
RSR. Simcock
R. Simcock
JWJ. Wright
J. Wright

25 October 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
RSR. Simcock
R. Simcock
LFL. Fallowfield
L. Fallowfield
KMK. Monson
K. Monson
ISI. Solis-Trapala
I. Solis-Trapala
LPL. Parlour
L. Parlour
VJV. Jenkins
V. Jenkins
Radiation treatment of head and neck cancer can cause chronic xerostomia which impairs patients' quality of life. The study reported here examined the efficacy of acupuncture in alleviating xerostomia symptoms especially dry mouth. A total of 145 patients with chronic radiation-induced xerostomia >18 months after treatments were recruited from seven UK cancer centres. The study employed a randomised crossover design with participants receiving two group sessions of oral care education and eight of acupuncture using standardised methods. Patient-reported outcome (PROs) measures were completed at baseline and weeks 5, 9, 13, 17, and 21. The primary outcome was improvement in dry mouth. Objective saliva measurements were also carried out. Acupuncture compared with oral care, produced significant reductions in patient reports of severe dry mouth (OR = 2.01, P = 0.031) sticky saliva (OR = 1.67, P = 0.048), needing to sip fluids to swallow food (OR = 2.08, P = 0.011) and in waking up at night to drink (OR = 1.71, P = 0.013). There were no significant changes in either stimulated or unstimulated saliva measurements over time. Eight sessions of weekly group acupuncture compared with group oral care education provide significantly better relief of symptoms in patients suffering from chronic radiation-induced xerostomia.

1 July 2016 in Clinical Oncology
Verified
Journal Article
Closed access
RSR. Simcock
R. Simcock
RSR. Simo
R. Simo

1 February 2012 in Clinical Oncology
Verified
Journal Article
Closed access
SHS. Heath
S. Heath
VWV. Willis
V. Willis
KAK. Allan
K. Allan
KPK. Purdie
K. Purdie
CHC. Harwood
C. Harwood
DGD.C. Gilbert
D.C. Gilbert